Joanna Baginska: The results for a melanoma expansion cohort of a phase 1B, multicenter, open-label study

Joanna Baginska, Lead Scientist at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“In this manuscript published just yesterday, we present the results for a melanoma expansion cohort of a phase 1B, multicenter, open-label study, in which the efficacy and safety of treatment with a ziv-aflibercept plus pembrolizumab were examined in patients with advanced PD-1-resistant disease.

The combination therapy demonstrated clinical activity and acceptable safety, despite the occurrence of adverse events. Changes in plasma analytes such as platelet-derived growth factor and PD-L1 were explored, indicating potential alterations in myeloid cell function. Higher levels of circulating CXCL10 in non-responding patients may reflect pro-tumor activity. Specific subsets of γδ T cells were associated with poor clinical outcomes, suggesting impaired γδ T-cell function in non-responding patients.

Congratulations to all colleagues! Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Juliana Vergara, Charlotte Abrecht, Margaret Hallisey, Jenna Dennis, Mariano Severgnini, Isabella Marciello, Osama Rahma, Michael Manos, Andy Brohl, Philippe Bedard, Elad Sharon, Beth Buchbinder and Steve Hodi.”

Source: Joanna Baginska/LinkedIn